|
|
Lymphomas
Common Treatments
|
Commonly Used Medications for Hodgkin Lymphoma
|
|
Chemotherapy |
|
bleomycin (Blenoxane) |
|
cyclophosphamide |
|
dacarbazine (DTIC-Dome) |
|
doxorubicin hydrochloride (Adriamycin) |
|
mechlorethamine (Mustargen) |
|
procarbazine (Matulane) |
|
vinblastine (Velban) |
|
vincristine (Oncovin) |
|
Corticosteroid |
|
prednisone |
|
Immunotherapy |
|
nivolumab (Opdivo) |
|
pembrolizumab (Keytruda) |
|
Targeted Therapy |
|
Monoclonal Antibody |
|
brentuximab vedotin (Adcetris) |
|
Some Possible Combinations |
|
ABVD: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban) and dacarbazine (DTIC-Dome) |
|
ABVD + R: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), dacarbazine (DTIC-Dome) and rituximab (Rituxan) |
|
BEACOPP: bleomycin (Blenoxane), etoposide (Etopophos), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine (Matulane) and prednisone |
|
ChlVPP: chlorambucil (Leukeran), vinblastine (Velban), procarbazine (Matulane) and prednisone |
|
ICE: ifosfamide, carboplatin and etoposide |
|
Stanford V: doxorubicin (Adriamycin), mechlorethamine (Mustargen), vincristine (Oncovin), bleomycin (Blenoxane), etoposide (Etopophos) and prednisone |
As of 5/7/20
|
Commonly Used Medications for Non-Hodgkin Lymphoma
|
|
Chemotherapy |
|
bendamustine (Bendeka, Treanda) |
|
carboplatin |
|
chlorambucil (Leukeran) |
|
cisplatin |
|
cyclophosphamide |
|
doxorubicin hydrochloride (Adriamycin) |
|
fludarabine (Fludara) |
|
methotrexate |
|
procarbazine (Matulane) |
|
vincristine (Oncovin) |
|
Corticosteroids |
|
dexamethasone |
|
methylprednisolone |
|
prednisone |
|
Immunotherapy |
|
CAR T-Cell Therapies |
|
axicabtagene ciloleucel (Yescarta) |
|
brexucabtagene autoleucel (Tecartus) |
|
tisagenlecleucel (Kymriah) |
|
Immune Checkpoint Inhibitor |
|
pembrolizumab (Keytruda) |
|
Immunomodulator Therapy |
|
lenalidomide (Revlimid) |
|
Radioimmunotherapy |
|
ibritumomab (Zevalin) |
|
Targeted Therapy |
|
BCL-2 Inhibitor |
|
venetoclax (Venclexta) |
|
Kinase Inhibitors |
|
acalabrutinib (Calquence) |
|
copanlisib (Aliqopa) |
|
duvelisib (Copiktra) |
|
ibrutinib (Imbruvica) |
|
idelalisib (Zydelig) |
|
zanubrutinib (Brukinsa) |
|
Monoclonal Antibodies |
|
brentuximab (Adcetris) |
|
mogamulizumab-kpkc (Poteligeo) |
|
obinutuzumab (Gazyva) |
|
polatuzumab vedotin-piiq (Polivy) |
|
rituximab (Rituxan) |
|
rituximab and hyaluronidase human (Rituxan Hycela) |
|
rituximab-abbs (Truxima) |
|
rituximab-pvvr (Ruxience) |
|
Proteasome Inhibitor |
|
bortezomib (Velcade) |
|
Some Possible Combinations |
|
BR: bendamustine (Bendeka, Treanda) and rituximab (Rituxan) |
|
CHOP: cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone |
|
CODOX-M/IVAC: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and intrathecal methotrexate, and cytarabine followed by high-dose systemic methotrexate and rituximab (Rituxan) |
|
CVP: cyclophosphamide, vincristine (Oncovin) and prednisone |
|
EPOCH-R: etoposide (Etopophos), prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin (Adriamycin) and rituximab (Rituxan) |
|
Hyper-CVAD: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and dexamethasone, alternating with high-dose methotrexate plus cytarabine and rituximab (Rituxan) |
|
P+BR: polatuzumab (Polivy), bendamustine (Bendeka, Treanda) and rituximab (Rituxan) |
|
R-CHOP: rituximab (Rituxan), cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone |
|
R-CVP: rituximab (Rituxan), cyclophosphamide, vincristine (Oncovin) and prednisone |
As of 7/24/20
|